iarjmcrIARJMCRIARJMCR2709-3220https://doi.org/10.47310/iarjmcr.2023.v04i01.005Brentuximab Vedotin Plus Cyclophosphamide, Vincristine and Prednisone (Bv+Cvp) for Refractory Systemic Anaplastic Large Cell Lymphoma: A Case Report in A Developing CountryWayanLosenAdnyanaSystemic Anaplastic Large Cell Lymphoma (ALCL) is a rare and very aggressive form Non-Hodgkin’s Lymphoma (NHL). ALCL rarely involves extensive bone tissue. Here we report a 16-year-old male with systemic ALCL with bone metastasis. Painless enlargement of the left thigh with a history of pelvic pain, the difficulty to walk and a prolonged fever of unknown origin have been complained in the last 6 months prior to hospital admission. The diagnosis of ALCL stage IV ECOG I was established and it was accompanied by a pathological fracture of the left sub trochanter of the femur. The patient was initially given 8 cycles of CHOP chemotherapy. Since the patient did not respond well to the therapy, the patient was given 7 cycles of CVP+brentuximab chemotherapy and the response was quite well. CVP+brentuximab chemotherapy in this case report can be used for refractory anaplastic large cell lymphoma.